Tamoxifen Showed Promising Results in a Preclinical Duchenne Muscular Dystrophy Study

Tamoxifen was developed by AstraZeneca for the treatment of breast cancer. However, new research suggests that it might have application as a potential therapy for Duchenne muscular dystrophy. Researchers from the Geneva-Lausanne School of Pharmaceutical Sciences of the University of Geneva and University of Lausanne administered tamoxifen to a mouse model of Duchenne muscular dystrophy (DMD) for a little longer than a year. The study‚Äôs lead author, Dr. Olivier M. Dorchies, said that treatment with tamoxifen “caused remarkable improvements of muscle force and of diaphragm and cardiac structure.” The results of this study will be published in the February 2013 issue of the American Journal of Pathology. Tamoxifen is currently being tested as a potential therapy for ALS in an ongoing Phase II clinical trial.

Click here to read more.

Share this: